NeoGenomics (NASDAQ:NEO) Reaches New 1-Year High After Analyst Upgrade

Shares of NeoGenomics, Inc. (NASDAQ:NEO) hit a new 52-week high during mid-day trading on Tuesday after Needham & Company LLC raised their price target on the stock from $19.00 to $22.00. Needham & Company LLC currently has a buy rating on the stock. NeoGenomics traded as high as $20.17 and last traded at $19.77, with a volume of 56031 shares changing hands. The stock had previously closed at $19.13.

A number of other analysts have also recently weighed in on the stock. Weiss Ratings raised shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 14th. Wall Street Zen raised shares of NeoGenomics from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. Benchmark raised their price target on shares of NeoGenomics from $11.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. TD Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a report on Wednesday, July 15th. Finally, Zacks Research lowered NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $18.17.

Key NeoGenomics News

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: NeoGenomics projected third-quarter 2026 revenue of $209 million, above the $205.8 million analyst consensus. Full-year revenue guidance of $802 million to $806 million was broadly in line with the $803.8 million consensus, supporting expectations for continued growth. NeoGenomics Names Warren Stone as Next CEO; Reports Q3 Revenue Guidance
• Positive Sentiment: Needham raised its price target for NeoGenomics (NEO) to $22 from $19 and maintained a Buy rating, implying meaningful upside based on the referenced share price. The broader analyst view was characterized as a Moderate Buy. Needham Raises NeoGenomics Price Target
• Neutral Sentiment: The company announced that Warren Stone will become its next chief executive and outlined executive and board succession changes, with board changes effective January 4, 2027. The plan may provide continuity, but investors are assessing how the transition could affect strategy and execution. NeoGenomics Announces Executive Leadership and Board Succession Plan
• Negative Sentiment: The leadership change overshadowed the favorable outlook, causing the stock to fall as investors reacted to CEO succession uncertainty. Coverage specifically described the decline as occurring despite the revenue beat and strong third-quarter outlook. NeoGenomics Sinks on CEO Succession Plan Despite Revenue Beat

Hedge Funds Weigh In On NeoGenomics

Several institutional investors have recently added to or reduced their stakes in the company. First Light Asset Management LLC boosted its position in NeoGenomics by 26.2% in the second quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company’s stock valued at $179,158,000 after buying an additional 2,549,545 shares in the last quarter. WINTON GROUP Ltd acquired a new stake in shares of NeoGenomics during the second quarter worth approximately $925,000. Integrated Wealth Concepts LLC acquired a new stake in shares of NeoGenomics during the second quarter worth approximately $99,000. NewEdge Advisors LLC bought a new position in shares of NeoGenomics in the second quarter valued at approximately $296,000. Finally, Squarepoint Ops LLC raised its stake in shares of NeoGenomics by 118.3% in the second quarter. Squarepoint Ops LLC now owns 222,036 shares of the medical research company’s stock valued at $3,240,000 after acquiring an additional 120,342 shares during the last quarter. 98.50% of the stock is owned by institutional investors.

NeoGenomics Stock Down 13.7%

The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of -41.25 and a beta of 1.79. The company has a current ratio of 3.60, a quick ratio of 3.35 and a debt-to-equity ratio of 0.48. The firm has a fifty day moving average price of $17.46 and a 200 day moving average price of $12.94.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.02. NeoGenomics had a negative return on equity of 1.99% and a negative net margin of 6.77%.The firm had revenue of $201.66 million during the quarter, compared to analysts’ expectations of $196.93 million. During the same period last year, the firm posted $0.03 EPS. The business’s revenue was up 11.2% on a year-over-year basis. Sell-side analysts anticipate that NeoGenomics, Inc. will post -0.09 EPS for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, Inc (NASDAQ:NEO) is a specialized oncology diagnostics company that provides testing services to hospitals, physicians, pathologists, pharmaceutical companies and other healthcare organizations. Its services support the diagnosis, classification and monitoring of cancer, helping guide treatment decisions and drug development.

The company offers a broad range of pathology and laboratory services, including molecular testing, next-generation sequencing, fluorescence in situ hybridization, cytogenetics, flow cytometry, immunohistochemistry and digital pathology.